ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 [Yahoo! Finance...
ALX Oncology Holdings Inc. (ALXO)
Company Research
Source: Yahoo! Finance
combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients' lives, today announced that results from a Phase 1b/2 combination trial evaluating ALX Oncology's evorpacept in combination with Jazz Pharmaceuticals' zanidatamab in HER2-positive and HER2-low metastatic breast cancer have been accepted for a poster spotlight presentation at the San Antonio Breast Cancer Symposium (SABCS), which will be held in San Antonio, Texas, from December 10-13, 2024. The Phase 1b/2 clinical trial is a two-part, open-label, multicenter study ( NCT05027139 ) that evaluated the potential of evorpacept in combination with zanidatamab as a novel treatment for pa
Show less
Read more
Impact Snapshot
Event Time:
ALXO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALXO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALXO alerts
High impacting ALX Oncology Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ALXO
News
- Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors [Yahoo! Finance]Yahoo! Finance
- ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical OfficerGlobeNewswire
- ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
ALXO
Earnings
- 11/7/24 - Beat
ALXO
Sec Filings
- 11/19/24 - Form 4
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- ALXO's page on the SEC website